Zucara Therapeutics Inc. is a biotechnology company based in Toronto, Canada, with an additional office in Vancouver. Founded in 2014, the company focuses on developing innovative therapeutics aimed at preventing hypoglycemia, or low blood sugar, in patients with diabetes. Its lead pre-clinical technology targets somatostatin type 2 receptors in the pancreas, which are inadequately regulated in individuals with Type 1 diabetes. By blocking these receptors, Zucara's treatment aims to prevent hypoglycemia and restore natural glucose levels in the bloodstream. This approach represents a significant advancement over existing therapies, which typically only address hypoglycemia after it has occurred, rather than preventing it from happening in the first place.
Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, focused on 3D bioprinting and tissue engineering. Founded in 2013, it develops bioprinted tissue therapeutics aimed at transforming disease treatment. The company utilizes proprietary microfluidic 3D bioprinting technology to create physiologically relevant living tissues, allowing for precise control over biomaterial composition and structure during fabrication. Aspect Biosystems offers contract testing services using its 3DAirwayALI human tissue model, catering to pharmaceutical firms and academic institutions engaged in research related to respiratory diseases. Through partnerships with leading researchers and industry innovators, the company aims to address significant challenges in regenerative medicine and advance the understanding of human tissue creation for medical research and therapeutic discovery.
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in developing treatments for patients with autoimmune diseases, organ transplantation needs, and neurodegenerative disorders. The company's lead product is tegoprubart, an anti-CD40L antibody designed to target the CD40L pathway, which has significant therapeutic potential. Additionally, Eledon focuses on disorders affecting the ear, nose, and throat, with its lead product OP0201 being a surfactant-based nasal aerosol aimed at patients at risk for otitis media. The company also explores foam-based drug delivery technologies, OP0101 and OP0102, for delivering medications to the ear, nose, and sinus cavities. Eledon Pharmaceuticals was previously known as Novus Therapeutics, Inc. before rebranding in January 2021.
vTv Therapeutics is a clinical-stage biopharmaceutical company based in High Point, North Carolina, dedicated to the discovery and development of orally administered small molecule therapeutics aimed at addressing unmet medical needs. The company has a diverse pipeline that includes drug candidates for various conditions, particularly focusing on central nervous system disorders, including Alzheimer's disease, and metabolic disorders such as type 2 diabetes. Key products under development include Azeliragon, which is in Phase II clinical trials for mild Alzheimer's disease, and TTP399, a liver-selective glucokinase activator that has shown promising results in treating type 2 diabetes. Other candidates such as TTP273, HPP737, HPP971, and HPP3033 are also being explored for chronic diseases. vTv Therapeutics emphasizes innovative technology and strategic collaborations to advance its research and development efforts, aiming to translate protein modulation into effective treatments. The company operates as a subsidiary of MacAndrews & Forbes Incorporated and was previously known as TransTech Pharma before rebranding in 2015.
Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.
Egle Therapeutics SAS is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing innovative immunotherapies that target immune suppressor regulatory T-cells (Tregs) for the treatment of oncology and autoimmune diseases. The company's research focuses on a proprietary drug pipeline that includes computationally designed IL-2 variants aimed at modulating Treg activity. This approach seeks to either engage or dis-engage Tregs, facilitating the development of therapies that can effectively combat cancer and other related conditions by addressing the immune suppression caused by Tregs. Egle Therapeutics aims to advance its unique portfolio to provide new treatment options in the healthcare field.
GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.
Abata Therapeutics is dedicated to developing innovative cell therapies aimed at treating autoimmune and inflammatory diseases, particularly progressive multiple sclerosis and type 1 diabetes. The company focuses on harnessing regulatory T cells (Tregs) to restore balance in the immune system, engineering these cells to specifically target disease-related antigens for precise treatment. This approach allows for effective disease management without the need for systemic immune suppression, enabling patients to maintain stable and active tissue residency. Founded by experts in immunology and cell therapy, Abata has garnered substantial investment from venture capital and biopharmaceutical firms, with the mission of translating advanced scientific research into meaningful therapies that enhance the quality of life for individuals affected by chronic autoimmune conditions.
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Seraxis is a biotechnology company founded in March 2013, with operations in Singapore and the United States, and a GMP lab located in Germantown, Maryland. The company specializes in developing innovative cell and encapsulation technologies aimed at creating a practical cell therapy for insulin-dependent diabetes. Their primary objective is to provide a long-term cure for diabetic patients that eliminates the need for immunosuppression, thereby improving the management of glucose levels through the production of insulin. Seraxis is structured to expedite the development of this therapy while maximizing value for its shareholders.
Protomer Technologies operates as a pre-clinical stage biotechnology company. Its research and technology development efforts are currently focused on metabolic diseases. The company was founded in 2014 and is headquartered in Pasadena, California.
Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products for diverse applications, including wound care, dermatology, animal health, eye care, and oral care. Based in Woodstock, Georgia, and incorporated in 1999, the company offers over 100 commercially available products worldwide. Its key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for managing dermatoses; Celacyn gel for scar management; and SebuDerm for seborrhea relief. Additionally, Sonoma provides Acuicyn for eye care, Microcyn for expedited wound healing, and various products targeting animal health, such as MicrocynAH and MicrocynVS. The company's focus on addressing unmet medical needs in chronic skin conditions significantly contributes to enhancing patient care while aiming to reduce overall healthcare costs. Sonoma Pharmaceuticals was previously known as Oculus Innovative Sciences, Inc. and rebranded in December 2016.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.
Enthera is an Italian biotech start-up focused on developing innovative therapeutic solutions for diabetes, gastrointestinal complications, and other intestinal disorders linked by shared biological pathways. Established in October 2016 through a partnership between BiovelocITA and scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, Enthera aims to address auto-immune disorders by targeting pathways involved in cell apoptosis across the gut, pancreas, and other organs. This approach seeks to enhance treatment options for challenging conditions such as type 1 diabetes and inflammatory bowel disease, thereby contributing to advancements in the management of intractable autoimmune diseases.
DiogenX is a preclinical stage biotech company based in Marseille, France, with research labs in Nice. Founded in 2019, the company specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of Type 1 and Type 2 diabetes. DiogenX aims to create a candidate molecule that regenerates insulin-producing pancreatic cells, potentially improving the quality of life and survival rates for individuals with diabetes. The innovative therapy is based on research conducted in the laboratory of Dr. Patrick Collombat, which positions DiogenX as a pioneer in the development of beta-cell regeneration treatments for diabetes.
SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.
Kriya Therapeutics, Inc. is a gene therapy company dedicated to designing and developing treatments for chronic diseases. Founded in 2019 and headquartered in Palo Alto, California, with an additional office in Durham, North Carolina, the company has established a fully integrated platform that consolidates the essential infrastructure and technology for creating, manufacturing, and developing gene therapies. Kriya Therapeutics employs a vector design platform that enhances its ability to undertake novel construct design, targeted sequence modification, and comprehensive data analysis. This approach aims to reduce immunogenicity and improve tissue specificity, ultimately enabling physicians to provide more effective therapeutic options for patients.
i2o Therapeutics is a biotech company that develops safe and effective oral formulations of therapies traditionally limited to injections. Using an innovative ionic liquid technology, it leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally. i2o is focused on creating the next generation of oral peptide and protein-based therapies. The company was founded in 2019 and based in Saratoga, California.
Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.
Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.
Immunocore Limited is a biotechnology company based in Abingdon, United Kingdom, with a focus on discovering and developing novel therapeutics for cancer, viral diseases, and autoimmune conditions. The company specializes in T cell receptor (TCR) technology, which allows it to create innovative bispecific immunotherapies. Its lead product candidate, IMCgp100, is currently undergoing clinical trials for the treatment of metastatic melanoma. Immunocore's proprietary platform enables efficient manufacturing of TCR-based drugs, addressing significant unmet medical needs. Founded in 1999 and previously known as Avidex Limited, Immunocore has expanded its operations with an additional office in Conshohocken.
IM Therapeutics develops personalized immunotherapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen (HLA) genes. Their lead candidate drug is an oral drug that starves the autoimmune process in type 1 diabetes (T1D) by blocking DQ8 on specific immune cells. Their goal is to preserve pancreatic beta-cell function and maintain normal insulin production in at-risk and early-stage patients with type 1 diabetes. They are leveraging Their HLA platform to expand their pipeline beyond T1D, to include drug development for Celiac disease (gluten sensitivity) as well as potential additional autoimmune diseases. It was founded in 2015 and is headquartered in Aurora, Colorado.
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Biolinq Inc. is a San Diego-based company that specializes in developing skin-applied electronic sensors for health monitoring. Founded in 2012, Biolinq focuses on creating a digital health platform that offers minimally invasive electrochemical biosensors. These sensors analyze biomarkers in interstitial fluid to deliver actionable health information, particularly for diabetic patients who need to monitor their blood glucose levels. By enabling continuous monitoring of multiple biomarkers, the company's technology aims to improve metabolic health and provide a more convenient alternative to traditional blood glucose monitoring methods.
ImmusanT is a biotechnology company that develops diagnostics and therapeutics for the diagnosis and treatment of celiac disease. The company focuses on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment. It develops Nexvax2, a therapeutic vaccine for treating, preventing, and diagnosing celiac disease. The company also develops a functional T-cell test to diagnose and monitor the maintenance of immune tolerance with peptide based therapy. ImmusanT was incorporated in 2010 and is based in Cambridge, Massachusetts.
Capillary Biomedical, Inc. is a medical device company founded in 2014 and located in Irvine, California. The company focuses on developing innovative technologies for diabetes management, particularly in simplifying glucose monitoring and insulin delivery. As a spin-out from the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University, Capillary Biomedical is dedicated to reducing the burden of diabetes on patients and the healthcare system. Its flagship product features a kink-proof, flexible, multiport cannula designed for reliable and comfortable insulin delivery, with an emphasis on a straightforward one-handed insertion process. This user-friendly design aims to assist diabetes patients in achieving better blood glucose control.
SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.
Bigfoot Biomedical, Inc. is a healthcare company focused on improving diabetes management for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company develops an advanced diabetes management system that integrates automated insulin delivery with cloud connectivity and user-friendly automation. This system aims to optimize insulin dosing and delivery through a cohesive ecosystem of medical devices, including an automated infusion pump and a connected insulin pen. Leveraging machine learning and secure consumer technologies, Bigfoot Biomedical provides a comprehensive digital platform that addresses the cognitive, emotional, and financial challenges associated with diabetes management. The company's innovative approach includes a first-of-its-kind monthly subscription service model, making diabetes care more accessible and efficient for patients.
Bigfoot Biomedical, Inc. is a healthcare company focused on improving diabetes management for individuals with Type 1 Diabetes. Established in 2014 and based in Milpitas, California, the company develops an advanced diabetes management system that integrates automated insulin delivery with cloud connectivity and user-friendly automation. This system aims to optimize insulin dosing and delivery through a cohesive ecosystem of medical devices, including an automated infusion pump and a connected insulin pen. Leveraging machine learning and secure consumer technologies, Bigfoot Biomedical provides a comprehensive digital platform that addresses the cognitive, emotional, and financial challenges associated with diabetes management. The company's innovative approach includes a first-of-its-kind monthly subscription service model, making diabetes care more accessible and efficient for patients.
SQZ Biotech is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients facing cancer, infectious diseases, and other serious health conditions. Utilizing its proprietary CellSqueeze technology, SQZ Biotech can deliver a variety of materials into diverse patient cell types, enabling the engineering of therapies that address a wide array of clinical challenges. The company aims to create well-tolerated cell therapies that not only enhance therapeutic benefits but also improve the overall patient experience compared to traditional cell therapy methods. Through a combination of internal research initiatives and external collaborations, SQZ Biotech is advancing a new generation of cellular therapies aimed at both immune activation and immune suppression.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who typically rely on insulin injections. The company was founded based on groundbreaking research by Professor Douglas Melton, which enabled the generation of functional, insulin-producing beta cells in the laboratory. This technology has been exclusively licensed to Semma Therapeutics, and the company aims to combine these proprietary cells with advanced devices to create a functional replacement for the missing beta cells without the need for immunosuppression. Headquartered in Cambridge, Massachusetts, with an additional office in Boston, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is dedicated to advancing this new therapeutic option to improve the lives of diabetes patients.
Diasome Pharmaceuticals is a clinical-stage company focused on developing innovative diabetes therapeutics. Based in Conshohocken, Pennsylvania, the company specializes in insulin-based therapies designed to optimize diabetes management for patients with Type 1 and Type 2 diabetes. Its flagship product, the hepatocyte directed vesicle (HDV), is a nanoscale carrier that effectively delivers insulin to the liver, enhancing insulin delivery systems and compatible with all existing insulin types and delivery methods. In addition to HDV, Diasome offers Oral HVD-I, a targeted oral insulin in pill or gel cap form, and both short-acting and long-acting injectable insulins. Founded in 2004, the company aims to improve blood sugar control and overall metabolic health through its proprietary technologies.
TetraGenetics, Inc. is a biotechnology company focused on developing therapeutic proteins and vaccines for the biopharmaceutical industry. Established in 2004 and based in Arlington, Massachusetts, the company utilizes its proprietary TetraExpress system to produce recombinant human ion channel proteins and other complex biologics. TetraGenetics specializes in the production of eukaryotic membrane and secretory proteins, which are often difficult to express using conventional systems. Among its products is IchVax, a recombinant subunit vaccine aimed at preventing white-spot disease in freshwater fish. The company is also engaged in a strategic research and development collaboration with Imbrium Therapeutics L.P., aiming to address autoimmune diseases and provide solutions for ion channel-related conditions. TetraGenetics' technology enables rapid production of properly folded, functional transmembrane proteins, positioning the company as a valuable player in the development of novel therapeutics and vaccines for both human and animal health.
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who typically rely on insulin injections. The company was founded based on groundbreaking research by Professor Douglas Melton, which enabled the generation of functional, insulin-producing beta cells in the laboratory. This technology has been exclusively licensed to Semma Therapeutics, and the company aims to combine these proprietary cells with advanced devices to create a functional replacement for the missing beta cells without the need for immunosuppression. Headquartered in Cambridge, Massachusetts, with an additional office in Boston, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is dedicated to advancing this new therapeutic option to improve the lives of diabetes patients.
GluSense Ltd. is engaged in the development of a miniature implantable continuous glucose sensor aimed at improving the quality of life for diabetes patients. Founded in 2007 and headquartered in Lod, Israel, the company is part of the Rainbow Medical innovation house. The sensor is designed to be implanted under the skin, providing accurate glucose measurements for over a year while significantly reducing the need for blood glucose calibrations. It transmits continuous glucose values wirelessly to external devices, such as smartphones or wearables, allowing individuals with diabetes to better manage their blood glucose levels and maintain them within a safe range.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics aimed at intercepting and preventing immune-mediated diseases. The company's product candidates include PRV-031, a monoclonal antibody currently in Phase III clinical trials for the interception of type 1 diabetes, and PRV-6527, an oral CSF-1R inhibitor in Phase IIa trials for Crohn's disease. Additionally, PRV-3279 has completed Phase 1b trials for lupus, while PRV-101 is being developed as a vaccine for coxsackie virus B infections, which may prevent the onset of type 1 diabetes. Provention Bio also has a licensing agreement with Amgen for PRV-015, a monoclonal antibody targeting celiac disease. Founded in 2016 and based in Oldwick, New Jersey, Provention Bio aims to address the high morbidity and costs associated with chronic autoimmune and inflammatory diseases through its innovative predictive and preventive therapeutic approaches.